Morgan Stanley Call 750 LONN 20.0.../ DE000MG83XE7 /
| 1/9/2025 1:17:43 PM | Chg.- | Bid10:00:37 PM | Ask10:00:37 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.041EUR | - | - Bid Size: - |
- Ask Size: - |
LONZA N | 750.00 CHF | 6/20/2025 | Call |
GlobeNewswire
8/26/2024
Simtra BioPharma Solutions Appoints Dr. Lidia Serina as Head of Development Sciences
GlobeNewswire
8/23/2024
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, G...
GlobeNewswire
8/8/2024
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
8/6/2024
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
6/14/2024
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at...
GlobeNewswire
5/30/2024
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively licens...
GlobeNewswire
5/15/2024
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ dec...
GlobeNewswire
5/8/2024
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
4/4/2024
Galapagos showcases innovative approach in hematological cancer care with clinical and translational...
GlobeNewswire
4/4/2024
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’...
GlobeNewswire
2/27/2024
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
1/4/2024
Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...
GlobeNewswire
12/19/2023
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufacture...
GlobeNewswire
12/9/2023
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 an...
GlobeNewswire
12/7/2023
Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at A...
GlobeNewswire
11/6/2023
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire
10/16/2023
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumoc...
GlobeNewswire
10/2/2023
Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
GlobeNewswire
9/20/2023
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023